D89.811 Chronic graft-versus-host disease

Name of the Condition

• Chronic graft-versus-host disease

Summary

Chronic graft-versus-host disease (cGVHD) is an immune-mediated condition that occurs when transplanted immune cells (graft) attack the recipient’s tissues (host) after allogeneic hematopoietic stem cell transplantation. It typically develops beyond 100 days post-transplant and can affect multiple organ systems, including the skin, mouth, eyes, gastrointestinal tract, liver, and lungs. cGVHD may present with features resembling autoimmune diseases, such as scleroderma, lichen planus, or Sjögren syndrome, and can significantly impact quality of life.

Causes

cGVHD is caused by donor immune cells recognizing the recipient’s tissues as foreign and mounting a persistent immune response. This occurs when the graft contains functional T cells that react against the host’s histocompatibility antigens. The risk increases with greater HLA mismatch between donor and recipient, prior acute GVHD, and the use of peripheral blood stem cells (vs. bone marrow). Non-transplant-related cGVHD may occur after transfusions in immunocompromised patients, where donor lymphocytes engraft and attack the host.

Risk Factors

• Allogeneic hematopoietic stem cell transplantation
• HLA mismatch between donor and recipient
• Prior episodes of acute GVHD
• Older age of the recipient
• Female donors for male recipients (due to prior pregnancies)
• Intensity of conditioning regimens
• Use of peripheral blood stem cells (vs. bone marrow)

Symptoms

• Skin: Erythema, sclerosis, lichen planus-like changes, or morphea-like plaques
• Mouth: Oral ulcers, xerostomia, or mucosal atrophy
• Eyes: Dryness, photophobia, or keratoconjunctivitis sicca
• Gastrointestinal tract: Dysphagia, esophageal strictures, or diarrhea
• Liver: Cholestasis or elevated liver enzymes
• Lungs: Bronchiolitis obliterans or restrictive lung disease
• Musculoskeletal: Joint stiffness or fasciitis

Diagnosis

Diagnosis of cGVHD is based on clinical findings, history of allogeneic transplantation, and exclusion of other conditions. Biopsy may confirm tissue involvement, and laboratory tests (e.g., liver function tests, pulmonary function tests) assess organ damage. The National Institutes of Health (NIH) consensus criteria are commonly used to classify and grade cGVHD severity. Imaging or endoscopy may be performed to evaluate specific organ systems.

Treatment Options

Treatment focuses on immunosuppression and symptom management. First-line therapy often includes corticosteroids (e.g., prednisone) with or without calcineurin inhibitors (e.g., tacrolimus). Second-line agents may include mycophenolate mofetil, rituximab, or extracorporeal photopheresis. Topical therapies (e.g., corticosteroids, tacrolimus) address skin or oral manifestations. Supportive care (e.g., lubricants, physical therapy) improves quality of life. Clinical trials may be considered for refractory cases.

Prognosis and Follow-Up

Prognosis varies depending on organ involvement and response to treatment. Mild cGVHD may resolve with minimal intervention, while severe or multi-organ disease can lead to significant morbidity. Regular follow-up is essential to monitor for progression, organ dysfunction, or secondary complications (e.g., infections, malignancy). Long-term management often requires multidisciplinary care, including dermatology, pulmonology, and gastroenterology.

Complications

• Organ fibrosis (e.g., pulmonary, hepatic)
• Infections due to immunosuppression
• Malnutrition or weight loss
• Ocular complications (e.g., corneal ulcers)
• Musculoskeletal contractures
• Secondary autoimmune disorders
• Increased risk of malignancy

Lifestyle & Prevention

• Adhere to prescribed immunosuppressive therapy
• Practice good oral hygiene to prevent oral cGVHD
• Use lubricating eye drops for dry eyes
• Avoid excessive sun exposure to protect skin
• Maintain a balanced diet to support nutritional status
• Engage in gentle exercise to preserve mobility
• Avoid smoking or exposure to respiratory irritants

When to Seek Professional Help

Seek medical attention if you experience:

• Worsening skin tightness, pain, or ulceration
• Difficulty swallowing or persistent oral pain
• Severe dry eyes or vision changes
• Persistent diarrhea or abdominal pain
• Shortness of breath or cough
• Unexplained weight loss or fatigue
• Signs of infection (e.g., fever, chills)

Tips for Medical Coders

Document the specific organ systems involved (e.g., skin, liver, lungs) and the timing of onset relative to transplantation. Note any prior acute GVHD, treatment regimens, and clinical manifestations to support code assignment. Ensure documentation aligns with the chronic nature of the condition and excludes acute GVHD if applicable. Use additional codes for related complications (e.g., infections, organ dysfunction) as needed.